Zura Bio Limited Stock Price, News & Analysis

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in two major investor conferences this November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 1:00 p.m. ET in Boston, and will host investor meetings at the Jefferies London Healthcare Conference on November 21, 2024, in London. Webcasts and replays will be available on Zura Bio's website's News & Events page for at least 30 days after the events.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced its participation in three upcoming investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 11:30 a.m. ET, the Stifel Immunology and Inflammation Virtual Summit on September 17 at 12:00 p.m. ET, and the Cantor Global Healthcare Conference on September 17 at 2:30 p.m. ET.

Zura Bio's senior leadership team will host investor meetings at these events, with the Stifel summit being virtual. Live webcasts and replays of the presentations will be available on the company's website for at least 30 days following each event.

Zura Bio (Nasdaq: ZURA) reported Q2 2024 financial results and business highlights. Key points include:

• Presented tibulizumab data at EULAR 2024, showing potential for dual inhibition of IL-17A and BAFF in autoimmune diseases
• Plans to initiate Phase 2 studies for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025)
• Appointed Robert Lisicki as CEO and formed Scientific Advisory Board
• Cash position of $188.4 million as of June 30, 2024, expected to support operations through 2027
• Q2 2024 net loss of $12.7 million ($0.17 per share)
• R&D expenses decreased to $5.5 million, while G&A expenses increased to $6.2 million

Zura Bio (Nasdaq: ZURA) has completed its exchange offer and consent solicitation for outstanding public and private placement warrants. The company issued 3,235,184 ordinary shares in exchange for tendered IPO warrants. Zura Bio will exercise its right to exchange all remaining untendered IPO warrants at a ratio of 0.27 Class A ordinary shares per warrant on August 27, 2024. As a result, no IPO warrants will remain outstanding, leading to their suspension from trading on Nasdaq as of August 26, 2024, and subsequent delisting. The company's Class A ordinary shares will continue to trade on Nasdaq under the symbol 'ZURA'.

Zura Bio (Nasdaq: ZURA) has announced the expiration and results of its exchange offer and consent solicitation for outstanding public and private placement warrants. 97.2% of public warrants and 69.0% of private placement warrants were validly tendered. The company expects to accept all validly tendered IPO warrants for exchange and settlement by August 12, 2024. The consent solicitation received approval for the Warrant Amendment, allowing Zura Bio to require conversion of remaining warrants at a 10% lower ratio than the exchange offer. Zura Bio plans to execute the Warrant Amendment and exercise its right to exchange all remaining untendered IPO warrants, after which no IPO warrants will remain outstanding.

Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.

Zura Bio presented data on tibulizumab (ZB-106) at EULAR 2024, demonstrating promising results in treating Sjogren's syndrome and rheumatoid arthritis (RA). The Phase 1 study showed tibulizumab was well-tolerated and effective in neutralizing IL-17A and BAFF, reducing B cell counts and modulating inflammatory mediators in 25 participants. Preclinical data in a RA mouse model indicated significant reductions in disease scores and inflammation when both IL-17A and BAFF were inhibited. The studies suggest tibulizumab's potential as a dual-pathway treatment for autoimmune diseases.

Zura Bio, a clinical-stage immunology company, has formed a Scientific Advisory Board (SAB) with experts in rheumatology, dermatology, and immunology. The board includes Johann Gudjonsson, Dinesh Khanna, Ajay Nirula, Michael Weinblatt, and Steven Ziegler. This initiative aims to advance their clinical and translational science efforts, particularly in Phase 2 clinical development for systemic sclerosis and hidradenitis suppurativa. The SAB will also focus on the roles of BAFF and IL-17A in autoimmune and inflammatory diseases, enhancing Zura Bio's research and clinical trials.

Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to illustrate the antibody's capacity to inhibit both pathways in a single therapy, potentially broadening its clinical applications across various autoimmune diseases. Zura Bio also disclosed timelines for Phase 2 trials: systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025.